Inhibition of cardiac HERG currents by the DNA topoisomerase II inhibitor amsacrine: Mode of action

British Journal of Pharmacology

Volumn 142, Issue 3, 2004, Pages 485-494

  Thomas, Dierk ^a   Hammerling, Bettina C ^a   Wu, Kezhong ^a   Wimmer, Anna Britt ^a   Ficker, Eckhard K ^b   Kirsch, Glenn E ^c   Kochan, Mary C ^c   Wible, Barbara A ^c   Scfaolz, Eberhard P ^a   Zitron, Edgar ^a   Kathöfer, Sven ^a   Kreye, Volker A W ^d   Katus, Hugo A ^a   Schoels, Wolfgang ^a   Karle, Christoph A ^a   Kiehn, Johann ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c ChanTest Inc   (United States)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Acute myeloid leukemia; Amsacrine; Arrhythmia; Channel; DNA topoisomerase II; Electrophysiology; Ion channels K +; Long QT syndrome; Sudden cardiac death; torsade de pointes

Indexed keywords

AMSACRINE; ANTINEOPLASTIC AGENT; DRUG RECEPTOR; GYRASE INHIBITOR; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL HERG; PROTEIN S6; VOLTAGE GATED POTASSIUM CHANNEL;

ARTICLE; CONCENTRATION RESPONSE; ELECTROPHYSIOLOGY; HEART PROARRHYTHMIA; HUMAN; HUMAN CELL; MALE; MICROELECTRODE; NONHUMAN; OOCYTE; PATCH CLAMP; POTASSIUM CURRENT; PRIORITY JOURNAL; PROTEIN DOMAIN; VOLTAGE CLAMP; XENOPUS LAEVIS;

AMSACRINE; ANIMALS; CELL LINE; CLONING, MOLECULAR; DNA TOPOISOMERASES, TYPE II; ENZYME INHIBITORS; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; MEMBRANE POTENTIALS; MUTATION; MYOCARDIUM; OOCYTES; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS, VOLTAGE-GATED; XENOPUS LAEVIS;

EID: 3042704530     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705795     Document Type: Article

References (36)

1. ABBOTT, G.W., SESTI, F., SPLAWSKI, I., BUCK, M.E., LEHMANN, M.H., TIMOTHY, K.W., KEATING, M.T. & GOLDSTEIN, S.A. (1999). MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell, 97, 175-187.
2. ARNAOUT, M.K., RADOMSKI, K.M., SRIVASTAVA, D.K., TONG, X., BELT, J.R., RAIMONDI, S.C., BEHM, F.G., SANTANA, V.M., CROM, W.R., MIRRO JR, J. & RIBEIRO, R.C. (2000). Treatment of childhood acute myelogenous leukaemia with an intensive regimen (AML-87) that individualizes etoposide and cytarabine dosages: short- and long-term effects. Leukemia, 14, 1736-1742.
3. DHALIWAL, H.S., SHANNON, M.S., BARNETT, M.J., PRENTICE, H.G., BRAGMAN, K., MALPAS, J.S. & LISTER, T.A. (1986). Treatment of acute leukaemia with m-AMSA in combination with cytosine arabinoside. Cancer Chemother. Pharmacol., 18, 59-62.
4. GRIFFIN, I.D., MAGUIRE, M.E. & MAYER, R.J. (1985). Amsacrine in refractory acute leukemia. Cancer Treat. Rep., 69, 787-789.
5. HAMILL, O.P., MARTY, A., NEHER, E., SAKMAN, B. & SIGWORTH, F.J. (1981). Improved patch clamp techniques for high resolution current recording from cells and cell free membrane patches. Pflug. Arch. Eur. J. Physiol., 391, 58-100.
6. JEHN, U. & HEINEMANN, V. (1991). New drugs in the treatment of acute and chronic leukemia with some emphasis on m-AMSA. Anticancer Res., 11, 705-711.
7. JURLINA, J.L., VARCOE, A.R. & PAXTON, J.W. (1985). Pharmacokinetics of amsacrine in patients receiving combined chemotherapy for treatment of acute myelogenous leukemia. Cancer Chemother. Pharmacol., 14, 21-25.
8. KANTARJIAN, H.M., ESTEY, E.H. & KEATING, M.A. (1996). New chemotherapeutic agents in acute myeloid leukemia. Leukemia, 10 (Suppl. 1), S4-S6.
9. KIEHN, J., THOMAS, D., KARLE, C.A., SCHÖLS, W. & KÜBLER, W. (1999). Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels. Naunyn-Schmiedeberg's Arch. Pharmacol., 359, 212-219.
10. KURYSHEV, Y.A., BROWN, A.M., WANG, L., BENEDICT, C.R. & RAMPE, D. (2000). Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels. J. Pharmacol. Exp. Ther., 295, 614-620.
11. LINSSEN, P., BRONS, P., KNOPS, G., WESSELS, H. & DE WITTE, T. (1993). Plasma and cellular pharmacokinetics of m-AMSA related to in vitro toxicity towards normal and leukemic clonogenic bone marrow cells (CFU-GM, CFU-L). Eur. J. Haematol., 50, 149-154.
12. MCLAUGHLIN, P., SALVADOR, P.G., CABANILLAS, F. & LEGHA, S.S. (1983). Ventricular fibrillation following AMSA. Uncomplicated retreatment following correction of hypokalemia. Cancer, 52, 557-558.
13. MILNES, J.T., CROCIANI, O., ARCANGELI, A., HANCOX, J.C. & WITCHEL, H.J. (2003). Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652. Br. J. Pharmacol., 139, 887-898.
14. MITCHESON, J.S., CHEN, J., LIN, M., CULBERSON, C. & SANGUINETTI, M.C. (2000a). A structural basis for drug-induced long QT syndrome. Proc. Natl. Acad. Sci. U.S.A., 97, 12329-12333.
15. MITCHESON, J.S., CHEN, J. & SANGUINETTI, M.C. (2000b). Trapping of a methanesulfonanilide by closure of the HERG potassium channel activation gate. J. Gen. Physiol., 115, 229-240.
16. MITCHESON, J.S. (2003). Drug binding to HERG channels: evidence for a 'non-aromatic' binding site for fluvoxamine. Br. J. Pharmacol., 139, 883-884.
17. NAPOLITANO, C., PRIORI, S. & SCHWARTZ, P.J. (1994). Torsade de pointes: mechanism and management. Drugs, 47, 51-65.
18. PAXTON, J.W., JURLINA, J.L. & FOOTE, S.E. (1986). The binding of amsacrine to human plasma proteins. J. Pharm. Pharmacol., 38, 432-438.
19. REDFERN, W.S., CARLSSON, L., DAVIS, A.S., LYNCH, W.G., MACKENZIE, I., PALETHORPE, S., SIEGL, P.K., STRANG, I., SULLIVAN, A.T., WALLIS, R., CAMM, A.J. & HAMMOND, T.G. (2003). Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res., 58, 32-45.
20. ROWE, J.M. (2000). Treatment of acute myelogenous leukemia in older adults. Leukemia, 14, 480-487.
21. Kr potassium channel. Cell, 81, 1-20.
22. + current: differential sensitivity to block by class III antiarrhythmic agents. J. Gen. Physiol., 96, 195-215.
23. SCHOLZ, E.P., ZITRON, E., KIESECKER. C., LUECK, S., KATHÖFER, S., THOMAS, D., WERETKA, S., PETH, S., KREYE, V.A.W., SCHOELS, W., KATUS, H.A., KIEHN, J. & KARLE, CA. (2003). Drug binding to aromatic residues in the HERG channel pore cavity as possible explanation for acquired long QT syndrome by antiparkinsonian drug budipine. Naunyn-Schmiedeberg's Arch. Pharmacol., 368, 404-414.
24. SCHWARTZ, C.L., BENDER, K.S., BURKE, P.J., KAN, J.S. & CIVIN, C.I. (1984). QT interval prolongation and cardiac dysrhythmia in a patient receiving amsacrine. Cancer Treat. Rep., 68, 1043-1044.
25. SEYMOUR, J.F. (1993). Induction of hypomagnesemia during amsacrine treatment. Am. J. Hematol., 42, 262-267.
26. SHINAR, E. & HASIN, Y. (1984). Acute electrocardiographic changes induced by amsacrine. Cancer Treat. Rep., 68, 1169-1172.
27. TESCHEMACHER, A.G., SEWARD, E.P., HANCOX, J.C. & WITCHEL, H.I. (1999). Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline. Br. J. Pharmacol., 128, 479-485.
28. THOMAS, D., WENDT-NORDAHL, G., RÖCKL, K., FICKER, E., BROWN, A.M. & KIEHN, J. (2001). High-affinity blockade of HERG human cardiac potassium channels by the novel antiarrhythmic drug BRL-32872. J. Pharmacol. Exp. Ther., 297, 753-761.
29. THOMAS, D., WU, K., KATHÖFER, S., KATUS, H.A., SCHOELS, W., KIEHN, I. & KARLE, C.A. (2003a). The antipsychotic drug chlorpromazine inhibits HERG potassium channels. Br. J. Pharmacol., 139, 567-574.
30. THOMAS, D., GUT, B., KARSAI, S., WIMMER, A.B., WU, K., WENDT-NORDAHL, G., ZHANG, W., KATHOFER, S., SCHOELS, W., KATUS, H.A., KIEHN, J. & KARLE, C.A. (2003b). Inhibition of cloned HERG potassium channels by the antiestrogen tamoxifen. Naunyn-Schmiedeberg's Arch. Pharmacol., 368, 41-48.
31. VAN HOFF, D.D., ELSON, D., POLK, G. & COLTMAN JR, C. (1980). Acute ventricular fibrillation and death during infusion of 4′-(9- acridinylamino)methanesulfon-m-anisidide (AMSA). Cancer Treat. Rep., 64, 356-358.
32. VISKIN, S. (1999). Long QT syndromes and torsade de pointes. Lancet, 354, 1625-1633.
33. WARMKE, J.W. & GANETZKY, B. (1994). A family of potassium channel genes related to eag in Drosophila and mammals. Proc. Natl. Acad. Sci. U.S.A., 91, 3438-3442.
34. WEERAPURA, M., NATTEL, S., CHARTIER, D., CABALLERO, R. & HEBERT, T.E. (2002). A comparison of currents carried by HERG, with and without coexpression of MiRP1, and the native rapid delayed rectifier current. Is MiRP1 the missing link? J. Physiol., 540, 15-27.
35. WEISS, R.B., GRILLO-LOPEZ, A.J., MARSONI, S., POSADA JR, J.G., HESS, F. & ROSS, B.J. (1986). Amsacrine-associated cardiotoxicity: an analysis of 82 cases. J. Clin. Oncol., 4, 918-928.
36. WINTON, E.F., HEARN, E.B., MARTELO, O., PRESANT, C.A., ADLER, S., VOGLER, W.R., RANEY, M., LOGAN, T., SILBERMAN, H.M. & OMURA, G.A. (1985). Sequentially administered 5-azacitidine and amsacrine in refractory adult acute leukemia: a phase I-II trial of the Southeastern Cancer Study Group. Cancer Treat. Rep., 69, 807-811.